Bilimsel çalışmalar

Prof. Dr. Meral Beksaç

911 yayın. Her yayının yanında bilginin kaynağı yazar.

Profile dön

  1. APOLLO: Phase 3 randomized study of subcutaneous Daratumumab plus Pomalidomide and Dexamethasone (D-Pd) versus Pomalidomide and Dexamethasone (Pd) alone in patients with Relapsed/Refractory Multiple Myeloma (RRMM)

    Oncology Research and Treatment, 2021

    Kaynak: ORCID

  2. Allogeneic hematopoietic cell transplantation (allo-HCT) outcomes in myeloma patients on renal replacement therapy: a report from the Chronic Malignancy Working Party (CMWP) of the European Society of Blood and Marrow Transplantation (EBMT)

    Bone Marrow Transplantation, 2021

    DOI 10.1038/s41409-020-01010-1 PMID 32741961 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  3. Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma

    Blood Cancer Journal, 2021

    DOI 10.1038/s41408-021-00562-9 PMID 34671024 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  4. Autologous Hematopoietic Cell Transplantation For Relapsed Multiple Myeloma Performed With Stem Cells Re-Mobilised Following A Prior AUTO-HCT - A Retrospective Study on Behalf of EBMT CMWP

    Bone Marrow Transplantation, 2021

    Kaynak: ORCID

  5. Bone marrow microenvironment interplay and current clinical practice in multiple myeloma: A review of the balkan myeloma study group

    Journal of Clinical Medicine, 2021

    DOI 10.3390/jcm10173940 PMID 34501388 12 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  6. CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma

    Molecular Cancer, 2021

    DOI 10.1186/s12943-021-01380-0 PMID 34090465 70 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  7. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

    The Lancet Haematology, 2021

    DOI 10.1016/s2352-3026(21)00278-7 PMID 34756169 50 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  8. Characteristics and Outcomes of Newly Diagnosed Multiple Myeloma Patients with and without Extramedullary Disease after Autologous Transplant and Maintenance Therapy: A Study from the Cmwp-EBMT

    Blood, 2021

    DOI 10.1182/blood-2021-152391 Kaynak: ORCID

  9. Comparison of Salvage Autologous Hematopoietic Cell Transplantation with Outcomes Following Selinexor Combinations Among Double/Triple Refractory Myeloma Patients

    Blood, 2021

    DOI 10.1182/blood-2021-148835 4 atıf (OpenAlex) Kaynak: ORCID

  10. Comparison of efficacy outcomes for Carfilzomib plus Dexamethasone and Daratumumab (KdD) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) and D-Pd in relapsed or refractory Multiple Myeloma

    Clinical Lymphoma Myeloma and Leukemia, 2021

    Kaynak: ORCID

  11. Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma

    Journal of Clinical Oncology, 2021

    DOI 10.1200/jco.21.01045 PMID 34520219 31 atıf (Europe PMC) Kaynak: ORCID

  12. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

    The Lancet Oncology, 2021

    DOI 10.1016/s1470-2045(21)00128-5 PMID 34087126 275 atıf (Europe PMC) Kaynak: ORCID

  13. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis

    New England Journal of Medicine, 2021

    DOI 10.1056/nejmoa2028631 PMID 34192431 574 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  14. Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study

    The Lancet Oncology, 2021

    DOI 10.1016/s1470-2045(20)30680-x PMID 33301738 53 atıf (Europe PMC) Kaynak: ORCID

  15. Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies

    Leukemia and Lymphoma, 2021

    DOI 10.1080/10428194.2020.1832672 PMID 33112184 15 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  16. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations

    British Journal of Haematology, 2021

    DOI 10.1111/bjh.17338 PMID 33724461 137 atıf (Europe PMC) Kaynak: ORCID

  17. HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA

    Journal of Hematology and Oncology, 2021

    DOI 10.1186/s13045-021-01066-6 PMID 33794982 142 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  18. Haplotypes rich in activating killer-cell immnuglobulin-like receptor genes are associated with delay on age of myeloma onset

    Clinical Lymphoma Myeloma and Leukemia, 2021

    Kaynak: ORCID

  19. Health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) treated with pomalidamide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes (PROs) in APOLLO

    Journal of Clinical Oncology, 2021

    DOI 10.1200/jco.2021.39.15_suppl.8046 1 atıf (OpenAlex) Kaynak: ORCID

  20. Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial

    British Journal of Haematology, 2021

    DOI 10.1111/bjh.17321 PMID 33555030 11 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  21. Highlighting the prognostic importance of measurable residual disease among acute myeloid leukemia risk factors,Akut myeloid lösemi risk faktörleri arasında ölçülebilir kalıntı hastalığın prognostik öneminin vurgulanması

    Turkish Journal of Hematology, 2021

    DOI 10.4274/tjh.galenos.2020.2020.0157 PMID 33112099 Açık erişimli tam metinKaynak: ORCID

  22. Immunoglobulin V(D) J Recombination, Protein Ubiquitination, Cell Adhesion and Sonic Hedgehog Gene Variants are detected among familial Multiple Myeloma subjects following whole exome sequencing

    Clinical Lymphoma Myeloma and Leukemia, 2021

    Kaynak: ORCID

  23. Pleural Involvement Upon Relapse of Myeloma Responding to Daratumumab Plus Carfilzomib: A Case Presentation and Literature Review

    Clinical Lymphoma, Myeloma and Leukemia, 2021

    DOI 10.1016/j.clml.2020.11.017 PMID 33380380 Kaynak: ORCID

  24. Pomalidomide and Dexamethasone with or without Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Updated Analysis of the Phase 3 Apollo Study

    Blood, 2021

    DOI 10.1182/blood-2021-146907 3 atıf (OpenAlex) Kaynak: ORCID

  25. Pomalidomide, bortezomib, and dexamethasone after 1 prior line of therapy in relapsed or refractory multiple myeloma (RRMM): A safety subanalysis of the phase 3 OPTIMISMM trial

    Clinical Lymphoma Myeloma and Leukemia, 2021

    Kaynak: ORCID

  26. Post-Induction Undetectable Minimal Residual Disease at 10 -5 Sensitivity Level within Marrow and/or Stem Cell Graft Overrides Cytogenetic High Risk

    Blood, 2021

    DOI 10.1182/blood-2021-148879 2 atıf (OpenAlex) Kaynak: ORCID

  27. Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation: F. Sahebi et al

    Transplantation and Cellular Therapy, 2021

    DOI 10.1016/j.jtct.2021.09.008 PMID 34543768 10 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  28. Postinduction minimal residual disease (MRD) within stem cell graft (gMRD) correlates with marrow MRD (mMRD) and progression free survival (PFS) following autologous stem cell transplantation

    Clinical Lymphoma Myeloma and Leukemia, 2021

    Kaynak: ORCID

  29. Prediction of Early Death and Severe Infections during Novel Agent-Based Induction Therapy in Newly-Diagnosed Multiple Myeloma: An Intergroup Analysis from the German Speaking Myeloma Multicenter Group, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology Foundation and the European Myeloma Network

    Blood, 2021

    DOI 10.1182/blood-2021-145289 Kaynak: ORCID

  30. Prognostic impact of early-versus-late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMT

    European Journal of Haematology, 2021

    DOI 10.1111/ejh.13602 PMID 33580608 Açık erişimli tam metinKaynak: ORCID

  31. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

    Leukemia, 2021

    DOI 10.1038/s41375-020-01016-0 PMID 32814840 103 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  32. Results of an International, Multi-Centre, Retrospective Study to Describe Treatment Pathways, Outcomes and Resource Use in Patients with Multiple Myeloma in Emerging Markets (INTEGRATE)

    Blood, 2021

    DOI 10.1182/blood-2021-147108 Kaynak: ORCID

  33. Safety of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Patients with Multiple Myeloma Presenting with Extramedullary Disease during the COVID-19 Pandemic

    Blood, 2021

    DOI 10.1182/blood-2021-152444 Kaynak: ORCID

  34. Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party

    Bone Marrow Transplantation, 2021

    DOI 10.1038/s41409-021-01286-x PMID 33976382 5 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  35. Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study

    Blood, 2021

    DOI 10.1182/blood-2021-146820 12 atıf (OpenAlex) Kaynak: ORCID

  36. Subgroup Analysis: Efficacy and Safety of Panobinostat in Combination with SC Bortezomib and Oral Dexamethasone in Multiple Myeloma Patients with Lenalidomide-Refractory Disease

    Blood, 2021

    DOI 10.1182/blood-2021-153694 Kaynak: ORCID

  37. Suppression of steroid 5α-reductase type I promotes cellular apoptosis and autophagy via PI3K/Akt/mTOR pathway in multiple myeloma

    Cell Death and Disease, 2021

    DOI 10.1038/s41419-021-03510-4 PMID 33627630 22 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  38. THE ROLE OF UPFRONT AUTOTRANSPLANTATION AND CONSOLIDATION THERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): FINAL ANALYSIS OF THE RANDOMIZED PHASE 3 EMN02/HO95 STUDY

    Haematologica, 2021

    Kaynak: ORCID

  39. The Outcome of Autologous Hematopoietic Cell Transplantation in Elderly Patients with Aggressive Non-Hodgkin Lymphoma

    Blood, 2021

    DOI 10.1182/blood-2021-153905 Kaynak: ORCID

  40. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

    The Lancet Oncology, 2021

    DOI 10.1016/s1470-2045(20)30756-7 PMID 33662288 215 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  41. Trends in Autologous Stem Cell Mobilisation Practices in Myeloma Patients in Ebmt Centers Between 2008 And 2017

    Bone Marrow Transplantation, 2021

    Kaynak: ORCID

  42. Updates from ICARIA-MM, a Phase 3 Study of Isatuximab (Isa) Plus Pomalidomide and Low-Dose Dexamethasone (Pd) vs Pd in Relapsed and Refractory Multiple Myeloma (RRMM)

    Clinical Lymphoma Myeloma and Leukemia, 2021

    Kaynak: ORCID

  43. Updates from ICARIA-MM, a phase 3 study of isatuximab (Isa) plus pomalidomide and low-dose dexamethasone (Pd) versus Pd in relapsed and refractory multiple myeloma (RRMM)

    Journal of Clinical Oncology, 2021

    DOI 10.1200/jco.2021.39.15_suppl.8017 20 atıf (OpenAlex) Kaynak: ORCID

  44. P-191: Comparison of efficacy outcomes for Carfilzomib plus Dexamethasone and Daratumumab (KdD) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) and D-Pd in relapsed or refractory Multiple Myeloma

    Clinical Lymphoma Myeloma & Leukemia, 2021

    DOI 10.1016/s2152-2650(21)02318-1 4 atıf (OpenAlex) Kaynak: OpenAlex

  45. MM-130: Updates from ICARIA-MM, a Phase 3 Study of Isatuximab (Isa) Plus Pomalidomide and Low-Dose Dexamethasone (Pd) vs Pd in Relapsed and Refractory Multiple Myeloma (RRMM)

    Clinical Lymphoma Myeloma & Leukemia, 2021

    DOI 10.1016/s2152-2650(21)01948-0 1 atıf (OpenAlex) Kaynak: OpenAlex

  46. Comparative Analysis and Validation of CIBMTR Early Relapse Risk Score with ISS and R-ISS: Single Center Experience from Ankara University

    Transplantation and Cellular Therapy, 2021

    DOI 10.1016/s2666-6367(21)00516-9 Açık erişimli tam metinKaynak: OpenAlex

  47. Impact of Peritransplant Metronidazole Use on Acute Graft Versus Host Disease in Allogeneic Hematopoietic Transplant Patients

    Transplantation and Cellular Therapy, 2021

    DOI 10.1016/s2666-6367(21)00343-2 Açık erişimli tam metinKaynak: OpenAlex

  48. NK Hücresel Tedaviler

    Turkiye Klinikleri Hematology - Special Topics, 2021

    Kaynak: OpenAlex

  49. Brentuksimab Vedotin Treatment in Relaps Refractory Hodgkin Lymphoma: A Single Center Experience

    LLM Dergi, 2021

    DOI 10.5578/llm.20219802 Açık erişimli tam metinKaynak: OpenAlex

  50. P-068: Haplotypes rich in activating killer-cell immnuglobulin-like receptor genes are associated with delay on age of myeloma onset

    Clinical Lymphoma Myeloma & Leukemia, 2021

    DOI 10.1016/s2152-2650(21)02202-3 Kaynak: OpenAlex